skip to main content
Idioma:
Resultados 1 2 3 next page
Refinado por: Nome da Publicação: Annals Of Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer A randomized phase II cardiac safety study (TRYPHAENA)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer A randomized phase II cardiac safety study (TRYPHAENA)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer A randomized phase II cardiac safety study (TRYPHAENA)

A. Schneeweiss S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J. H Seo; Y.-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés

Annals of Oncology Oxford v. 24, n. 9, p. 2278-2284, 2013

Oxford 2013

Acesso online. A biblioteca também possui exemplares impressos.

2
Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) Progression-free survival (PFS) subgroup analyses in BOLERO-4
Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) Progression-free survival (PFS) subgroup analyses in BOLERO-4
Material Type:
Artigo de Congresso 		Adicionar ao Meu Espaço

Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) Progression-free survival (PFS) subgroup analyses in BOLERO-4

T Bachelot M Royce; C Villanueva; F. Melo Cruz; Roberto Hegg; C Falkson; J Jeong; V Srimuninnimit; C. H Arce; A Ridolfi; 42nd European-Society-for-Medical-Oncology Congress (ESMO) (42. 2017 Madrid, Spain)

Annals of oncology v. 28, suppl.5, 2017

Oxford 2017

Acesso online. A biblioteca também possui exemplares impressos.

3
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

T Bachelot E Ciruelos; A Schneeweiss; F Puglisi; T Peretz-Yablonski; I Bondarenko; S Paluch-shimon; A Wardley; J. -L Merot; Roberto Hegg

Annals of oncology v. 30, n. 5, p. 766-773, 2019

Oxford 2019

Acesso online. A biblioteca também possui exemplares impressos.

4
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Harbeck, N. ; Rastogi, P. ; Martin, M. ; Tolaney, S.M. ; Shao, Z.M. ; Fasching, P.A. ; Huang, C.S. ; Jaliffe, G.G. ; Tryakin, A. ; Goetz, M.P. ; Rugo, H.S. ; Senkus, E. ; Testa, L. ; Andersson, M. ; Tamura, K. ; Del Mastro, L. ; Steger, G.G. ; Kreipe, H. ; Hegg, R. ; Sohn, J. ; Guarneri, V. ; Cortés, J. ; Hamilton, E. ; André, V. ; Wei, R. ; Barriga, S. ; Sherwood, S. ; Forrester, T. ; Munoz, M. ; Shahir, A. ; San Antonio, B. ; Nabinger, S.C. ; Toi, M. ; Johnston, S.R.D. ; O’Shaughnessy, J. ; Jimenez, M.M. ; Johnston, S. ; Boyle, F. ; Steger, G.G. ; Neven, P. ; Jiang, Z. ; Campone, M. ; Huober, J. ; Shimizu, C. ; Cicin, I. ; Wardley, A. ; Tolaney, S.M. ; Abuin, G.G. ; Zarba, J. ; Lim, E. ; Sant, P. ; Liao, N. ; Christiansen, B. ; Eigeliene, N. ; Martin-Babau, J. ; Ettl, J. ; Mavroudis, D. ; Chiu, J. ; Boer, K. ; Nagarkar, R. ; Paluch-Shimon, S. ; Moscetti, L. ; Sagara, Y. ; Kim, S.-B. ; Maciel, M.M. ; Tjan-Heijnen, V. ; Broom, R. ; Lacko, A. ; Schenker, M. ; Volkov, N. ; Sim Yap, Y. ; Coccia-Portugal, M. ; Ángel García Sáenz, J. ; Andersson, A. ; Chao, T.-Y. ; Gokmen, E. ; Harputluoglu, H. ; Berzoy, O. ; Patt, D. ; McArthur, H. ; Chew, H. ; Chalasani, P. ; Kaufman, P. ; Tedesco, K. ; Graff, S.L.

Annals of oncology, 2021-12, Vol.32 (12), p.1571-1581 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Schneeweiss, A. ; Chia, S. ; Hickish, T. ; Harvey, V. ; Eniu, A. ; Hegg, R. ; Tausch, C. ; Seo, J.H. ; Tsai, Y.-F. ; Ratnayake, J. ; McNally, V. ; Ross, G. ; Cortés, J.

Annals of oncology, 2013-09, Vol.24 (9), p.2278-2284 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
Material Type:
Artigo 		Adicionar ao Meu Espaço

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

Martín, M. ; Chan, A. ; Dirix, L. ; O’Shaughnessy, J. ; Hegg, R. ; Manikhas, A. ; Shtivelband, M. ; Krivorotko, P. ; Batista López, N. ; Campone, M. ; Ruiz Borrego, M. ; Khan, Q.J. ; Beck, J.T. ; Ramos Vázquez, M. ; Urban, P. ; Goteti, S. ; Di Tomaso, E. ; Massacesi, C. ; Delaloge, S.

Annals of oncology, 2017-02, Vol.28 (2), p.313-320 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

Bell, R. ; Brown, J. ; Parmar, M. ; Toi, M. ; Suter, T. ; Steger, G.G. ; Pivot, X. ; Mackey, J. ; Jackisch, C. ; Dent, R. ; Hall, P. ; Xu, N. ; Morales, L. ; Provencher, L. ; Hegg, R. ; Vanlemmens, L. ; Kirsch, A. ; Schneeweiss, A. ; Masuda, N. ; Overkamp, F. ; Cameron, D.

Annals of oncology, 2017-04, Vol.28 (4), p.754-760 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)
IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)

Schmid, P. ; Adams, S. ; Rugo, H.S. ; Schneeweiss, A. ; Barrios, C.H. ; Iwata, H. ; Dieras, V. ; Hegg, R. ; Im, S.-A. ; Wright, G.S. ; Henschel, V. ; Molinero, L. ; Chui, S.Y. ; Funke, R. ; Husain, A. ; Winer, E.P. ; Loi, S. ; Emens, L.A.

Annals of oncology, 2018-10, Vol.29, p.viii707-viii708 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial
Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial

Korach, J. ; Freyer, G. ; Banerjee, S. ; Asher, R. ; Cosin, J. ; Oza, A.M. ; Poveda, A.M. ; Di Napoli, M. ; Scott, C. ; Lapresa, M. ; Heitz, F. ; Takehara, K. ; Sonke, G.S. ; Tjulandin, S. ; Kim, J.-W. ; Hegg, R. ; Vergote, I.B. ; Turner, S. ; Pujade-Lauraine, E.

Annals of oncology, 2018-10, Vol.29, p.viii340-viii341 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Miles, D. ; Gligorov, J. ; Cameron, D. ; Xu, B. ; Semiglazov, V. ; Reinisch, M. ; Patre, M. ; Morales, L. ; Patel, S.L. ; Barata, T. ; Xu, B. ; Shao, Z. ; Wang, X. ; Geng, C. ; Yan, X. ; Tong, Z. ; Sun, T. ; Yang, J. ; Liu, Q. ; Zhang, S. ; De Laurentiis, M. ; Santoro, A. ; Colleoni, M. ; Cortesi, L. ; Placido, S. ; Ferrau, F. ; Del Mastro, L. ; Tonini, G. ; Montemurro, F. ; Bianchi, G. ; Prete, S. ; Allegrini, G. ; Naso, G. ; Vici, P. ; Loirat, D. ; Tredan, O. ; Gligorov, J. ; Timar David, M. ; Dohollou, N. ; Spano, J.-P. ; Mansi, L. ; Andrade, L. ; Damian, F. ; Aleixo, S. ; Junior, R. ; Reinisch, M. ; Grischke, E.-M. ; Harbeck, N. ; Peters, U. ; Fischer, D. ; Forstbauer, H. ; Warner, E. ; Bouganim, N. ; Vandenberg, T. ; Pavic, M. ; Robinson, A. ; Califaretti, N. ; Alacacioglu, A. ; Gumus, M. ; Yalcin, B. ; Cicin, I. ; Kose, F. ; Cubukcu, E. ; Wardley, A. ; Miles, D. ; Gupta, S. ; Mohapatra, P. ; Ghadyalpatil, N. ; Singhal, M. ; Agarwal, A. ; Wolf, I. ; Gal Yam, E. ; Yerushalmi, R. ; Peretz, T. ; Ben Baruch, N. ; Hamilton, E. ; Brufsky, A. ; Wright, G. ; Graff, S. ; Semiglazov, V. ; Ruiz Borrego, M. ; Merino, L. ; Guerra Martinez, J. ; Ohtani, S. ; Inoue, K. ; Ito, Y. ; Niikura, N. ; Sagara, Y. ; Yanagita, Y. ; Kaen, D. ; Nervo, A. ; Melichar, B. ; Sormova, P. ; Sufliarsky, J. ; Kakalejcik, M. ; Belbaraka, R. ; Errihani, H. ; Le Than, D. ; Pham, D. ; Papandreou, C.

Annals of oncology, 2021-08, Vol.32 (8), p.994-1004 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar
  1. Antes de2013  (3)
  2. 2013Até2014  (4)
  3. 2015Até2016  (2)
  4. 2017Até2019  (10)
  5. Após 2019  (9)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.